| Date | Title | Description | Source |
| 20.03.2024 | Startup Lands $150M for Delicate Dance Between Cancer Cells ... | Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of ... | medcitynew... |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID... | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of ... | einpresswi... |
| 08.09.2021 | bluebird bio : Secures $75 Million in Private Placement Equi... | bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 mi... | marketscre... |
| 07.06.2021 | BLUEBIRD BIO, INC.
Bluebird bio : Announces the Lifting of ... | bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia St... | marketscre... |
| 26.02.2021 | bluebird bio to Present at Cowen Health Care Conference | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 26, 2021--
bluebird bio, Inc. (NASDAQ: BLUE) today announced ... | oaoa.com/n... |
| 24.02.2021 | The New England Journal of Medicine Publishes Results from P... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2021--
Results from the pivotal Phase 2 KarMMa study eval... | oaoa.com/n... |
| 05.06.2018 | We just got a lot of updates on the state of cancer treatmen... | ASCO
Advertisement
Over the weekend at the American Society of Clinical Oncologists meeting, a lot o... | businessin... |
| 09.04.2018 | Novartis just handed out a $8.7 billion endorsement for new ... | Reuters
Novartis CEO Vas Narasimhan
Advertisement
Novartis is acquiring gene therapy company AveXis ... | businessin... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboratio... | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven experti... | ncltv.co.u... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboratio... | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven experti... | nclim.co.u... |
| 31.10.2016 | Third Rock Ventures closes $616 million healthcare fund | Fund IV has not yet begun investing, according to a company representative, but the firm has establi... | medcitynew... |
| 20.07.2016 | Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; S... | - | mpmcapital... |
| 15.01.2015 | Just a cool #JPM15 Bluebird Bio slide that shows its impress... | The company’s stock has just killed it in the past year – from $BLUE trading around $17 per share a ... | medcitynew... |
| 09.01.2014 | bluebird bio Appoints Dr James Mandell to its Board of Direc... | CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 9, 2014– bluebird bio, a clinical-stage biotechnology company ... | tvm-lifesc... |
| 28.08.2013 | 11 health companies make the World Economic Group tech pione... | Nearly one-third of the 36 emerging technology pioneers chosen by the World Economic Forum this year... | medcitynew... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenole... | medcitynew... |
| 25.07.2012 | bluebird bio Closes $60M Series D Funding | bluebird bio, a Cambridge, Mass., and Paris-based developer of gene therapies for severe genetic dis... | finsmes.co... |
| 25.07.2012 | bluebird bio Secures $60 Million in Oversubscribed Financing | Proceeds will Further Strengthen bluebird’s Proprietary Gene Therapy Platform and Advance Multiple C... | tvm-lifesc... |
| 25.07.2012 | bluebird bio Secures $60 Million in Oversubscribed Financing | Proceeds will Further Strengthen bluebird’s Proprietary Gene Therapy Platform and Advance Multiple C... | forbion.co... |
| 25.07.2012 | bluebird bio Sings to $60 million Series D |
CAMBRIDGE, MA, Leader in the development of innovative gene therapies for severe genetic disorders... | vcnewsdail... |
| 20.04.2011 | bluebird bio Raises $30M | bluebird bio, a Cambridge, Mass. and Paris, France-based developer of innovative gene therapies for ... | finsmes.co... |
| 20.04.2011 | bluebird bio Secures Additional $30 Million in Financing | - | forbion.co... |
| 20.04.2011 | bluebird bio Secures Additional $30 Million in Financing | ARCH Venture Partners Joins Investor Team
New Financing Will Further Advance the Beta-Thalassemia, ... | tvm-lifesc... |
| 22.03.2011 | Bovie Medical names new president, shuffles board | Personne... | Bovie Medical Corp. (NYSE:BVX) announced a flurry of personnel moves in its corner office and board ... | massdevice... |
| 15.09.2010 | Bluebird Bio, Third Rock & Genzyme’s Gene Therapy Bet, S... | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Genzyme and Third Rock Ventures bet... | xconomy.co... |
| - | Third Rock Ventures closes $616 million healthcare fund | Third Rock Ventures announced Monday that it had closed its fourth fund — it’s largest, Third Rock V... | medcitynew... |
| - | Just a cool #JPM15 Bluebird Bio slide that shows its impress... | Bluebird Bio‘s work has been at the epicenter of gene therapy, working on a litany of fields that in... | medcitynew... |
| - | bluebird bio Reports Fourth Quarter and Full Year 2020 Finan... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 23, 2021--
bluebird bio, Inc. (NASDAQ:BLUE) today reported fi... | oaoa.com/n... |
| - | bluebird bio Provides Updated Findings from Reported Case of... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 10, 2021--
bluebird bio, Inc. (Nasdaq: BLUE) announced today ... | oaoa.com/n... |
| - | Bluebird Bio gene therapy wins first FDA approval for rare b... | A Bluebird Bio gene therapy that treats the rare blood disorder beta thalassemia is now approved by ... | medcitynew... |
| - | 11 health companies make the World Economic Group tech pione... | Nearly one-third of the 36 emerging technology pioneers chosen by the World Economic Forum this year... | medcitynew... |
| - | An unmet medical need in treating rare genetic blood disorde... | The hemoglobinopathies are a group of inherited blood disorders caused by mutations affecting the gl... | statnews.c... |
| - | bluebird bio Presents Long-Term Data for elivaldogene autote... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 15, 2021--
bluebird bio, Inc. (Nasdaq: BLUE) announced new da... | oaoa.com/n... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia ... | Company name: bluebird bio.
Industry: Biotechnology.
Location: Cambridge, Massachusetts.
Product: Ge... | medcitynew... |
